|本期目录/Table of Contents|

[1]任超.尿液中miRNA-24-3p联合miRNA-222-3p检测在前列腺癌中的诊断及临床意义[J].天津医科大学学报,2022,28(02):181-185.
 REN Chao.Diagnosis and clinical significance of miR-24b-3p combined with miR-222-3p in urinary in prostate cancer[J].Journal of Tianjin Medical University,2022,28(02):181-185.
点击复制

尿液中miRNA-24-3p联合miRNA-222-3p检测在前列腺癌中的诊断及临床意义(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
28卷
期数:
2022年02期
页码:
181-185
栏目:
临床医学
出版日期:
2022-03-20

文章信息/Info

Title:
Diagnosis and clinical significance of miR-24b-3p combined with miR-222-3p in urinary in prostate cancer
文章编号:
1006-8147(2022)02-0181-05
作者:
任超12
(1.天津医科大学人民医院临床学院,天津300121;2.天津市滨海新区大港医院检验科,天津300270)
Author(s):
REN Chao12
(1. Tianjin Union Medical Center,Tianjin Medical University,Tianjin 300121,China; 2. Department of Clinical Laboratory,Dagang Hospital of Tianjin Binhai New Area,Tianjin 300270,China)
关键词:
miRNAs前列腺癌生物标志物qRT-PCR
Keywords:
miRNAsprostate cancerdiagnostic biomarkerqRT-PCR
分类号:
R447
DOI:
-
文献标志码:
A
摘要:
目的:建立尿液miRNA检测板,作为诊断前列腺癌(PC)的无创性生物标志物。方法:采用miRNAs芯片分析对照1组(6名)及PC1组(18例)中miRNAs表达,并进一步利用qRT-PCR对20名对照2组及59例PC2组(GS2 6组22例,GS2 7组19例,GS28组18例)尿液、血清标本进行差异基因的进一步验证。应用受试者工作特征(ROC)曲线分析组合诊断模型的准确真实性。结果:获得在PC1组中20个miRNAs差异表达谱,与对照1组相比,miRNA-24-3p及miRNA-222-3p显著表达下调(T=5.79、4.59,均P<0.05),用于PC诊断检测。在扩大样本量的PC患者尿液及血清样本中,根据GS分组的GS26、GS27及GS28组中,与对照2组相比,miRNA-24-3p联合miRNA-222-3p表达水平也都显著下调(t=3.89,P<0.05),ROC分析联合诊断模型具有较高的准确度(曲线下面积为0.93,OR=1.37,95% CI:0.92~1.76,P=0.02)。结论:在尿液、血清样本中建立了miRNA-24-3p联合miRNA-222-3p组合模型,可作为诊断PC的无创性生物标志物。
Abstract:
Objective: To establish a urine miRNA detection panel as a non-invasive biomarker helping diagnosing prostate cancer (PC).Methods: A total of 18 PC1 group patients and 6 normal control group 1 urinary samples were analyzed through a miRNA microarray process,and further using quantitative real-time polymerase chain reaction,differentially expressed miRNAs were detected in urinary and serum of the PC2 patients(n=59),including 22 GS2 6,19 GS2 7 and 18 samples of GS2 8,20 normal samples as the control group 2.The accuracy and authenticity of the combined diagnostic model should be analyzed by the receiver operating characteristic(ROC)curve. Results: The differential expression profiles of 20 miRNAs in PC1 group were identified,including miR-24b-3p and miR-222-3p for PC detection,compared with control group1(T=5.79,4.59,all P<0.05). Moreover,in the urine and serum samples of PC samples with expanded samples,the expression of miR-24b-3p combined with miR-222-3p in GS6,GS7 and GS8 groups grouped according to GS score were significantly decreased than those in the control group 2(t=3.89,P<0.05). The combined diagnostic model of ROC analysis has high accuracy(area under curve=0.93,OR=1.37,95% CI:0.92-1.76,P=0.02). Conclusion: A combined model of miR-24-3p and miR-222-3p in urinary and serum samples are established,which can be acted as a non-invasive biomarker helping diagnosing PC.

参考文献/References:

[1] KOMURA K,SWEENEY C J,INAMOTO T,et al. Current treatment strategies for advanced prostate cancer[J]. Int J Urol,2018,25(3): 220-231.
[2] HEIDENREICH A,BELLMUNT J,BOLLA M,et al. EAU guidelines on prostate cancer. Part I:screening,diagnosis,and treatment of clinically localised disease[J]. Actas Urol Esp,2011,35(9):501-514.
[3] KLOTZ L,ZHANG L,LAM A,et al. Clinical results of long-term follow-up of a large,active surveillance cohort with localized prostate cancer[J]. J Clin Oncol,2010,28(1):126-131.
[4] HE L,HANNON G J. MicroRNAs:small RNAs with a big role in gene regulation[J]. Nat Rev Genet,2004,5(7):522-531.
[5] KOZOMARA A,GRIFFITHS-JONES S.miRBase:annotating high confidence microRNAs using deep sequencing data[J]. Nucleic Acids Res,2014,42(Database issue):D68-D73.
[6] HA M,KIM V N. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol,2014,15(8):509-524.
[7] MATSUZAKI K,FUJITA K,TOMIYAMA E,et al. MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer[J]. Transl Androl Urol,2021,10(4):1918-1927.
[8] SHIN S,PARK Y H,JUNG S H,et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J]. NPJ Genom Med,2021,6(1):45.
[9] FABRIS L,CEDER Y,CHINNAIYAN A M,et al. The potential of micrornas as prostate cancer biomarkers[J]. Eur Urol,2016,70(2): 312-322.
[10] FREDSOE J,RASMUSSEN A K I,THOMSEN A R,et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine[J]. Eur Urol Focus,2018,4(6):825-833.
[11] LIU R S C,OLKHOV-MITSEL E,JEYAPALA R,et al. Assessment of serum microrna biomarkers to predict reclassification of prostate cancer in patients on active surveillance[J]. J Urol,2018,199(6): 1475-1481.
[12] SUN Y,CHEN G,HE J,et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer[J]. Bioengineered,2021,12(1):325-340.
[13] ANDERSEN C L,JENSEN J L,ORNTOFT T F. Normalization of real-time quantitative reverse transcription-PCR data:a model-based variance estimation approach to identify genes suited for normalization,applied to bladder and colon cancer data sets[J]. Cancer Res,2004,64(15):5245-5250.
[14] FREDS?覫E J,RASMUSSEN A K I,MOURITZEN P,et al. A five-microRNA model(pCaP)for predicting prostate cancer aggressiveness using cell-free urine[J]. Int J Cancer,2019,145(9):2558-2567.
[15] ZHANG S,LIU C,ZOU X,et al. MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer[J]. PeerJ,2021,9:e11441.
[16] LIN Y,CAO H,TIAN Y,et al. MiR-24-3p stimulates migration,invasion and proliferation of prostate cancer cells by targeting suppressor of cytokine signaling 6[J]. Int J Clin Exp Pathol,2018,11(3): 1803-1810.
[17] LI X,HAN X,WEI P,et al. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1[J]. Cancer Biol Ther,2020,21(5):452-462.
[18] KREBS M,SOLIMANDO A G,KALOGIROU C,et al. MiR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from sunitinib in vitro[J]. J Clin Med,2020,9(3):670-677.

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
 YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(02):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
 WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
 ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
 SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(02):401.
[7]管明秀,周云丽,王 萌,等.TuM2-PK,tPSA,fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140.
 GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(02):140.
[8]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
 LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(02):93.
[9]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
 ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(02):99.
[10]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
 BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(02):103.

备注/Memo

备注/Memo:
作者简介 任超(1987-),女,技师,硕士在读,研究方向:临床检验诊断;通信作者:刘蕊,E-mail:renchao417@126.com。
更新日期/Last Update: 2022-03-20